Contrasting LENZ Therapeutics (NASDAQ:LENZ) & Anthera Pharmaceuticals (OTCMKTS:ANTH)

LENZ Therapeutics (NASDAQ:LENZ) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Volatility and Risk

LENZ Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.

Valuation & Earnings

This table compares LENZ Therapeutics and Anthera Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09 million	10.81	-$82.13 million	($3.60)	-1.83
Anthera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Anthera Pharmaceuticals has lower revenue, but higher earnings than LENZ Therapeutics.

Profitability

This table compares LENZ Therapeutics and Anthera Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Anthera Pharmaceuticals	N/A	N/A	N/A

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for LENZ Therapeutics and Anthera Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1	2	5	0	2.50
Anthera Pharmaceuticals	0	0	0	0	0.00

LENZ Therapeutics presently has a consensus target price of $29.80, suggesting a potential upside of 352.89%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe LENZ Therapeutics is more favorable than Anthera Pharmaceuticals.

Summary

LENZ Therapeutics beats Anthera Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.